At ASCO, Blueprint presented positive data on its RET inhibitor pralsetinib across a range of cancers and in a call with investors discussed regulatory plans in lung and thyroid cancers.
In another study at ASCO, the immunotherapy showed benefits as maintenance therapy in advanced bladder cancer patients, regardless of PD-L1 expression status.
A pilot project showed that clinics using the InheRET tool were able to gather more complete family history information from patients, which is important for further cancer risk evaluation.
The platform was used to subtype patients in a Phase II trial and found that patients in the claudin-low subgroup had the best two-year progression-free survival on pembrolizumab.
The company maintained that poziotinib could provide clinical benefit in EGFR exon 20-mutated NSCLC and are adjusting trial designs in the hopes of maximizing its efficacy.
Trodelvy is an antibody-drug conjugate that targets the antigen Trop-2 and is intended for metastatic triple-negative breast cancer patients who have received at least two prior therapies.
Oncolytics will run two biomarker validation studies before pursuing the first registration enabling trial in HR-positive, HER2-negative breast cancer for Reolysin.
